Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

CompletedOBSERVATIONAL
Enrollment

299

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Melanoma
Interventions
BIOLOGICAL

Intron A (interferon alfa-2b; SCH 30500)

The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m\^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m\^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00723710 - Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) | Biotech Hunter | Biotech Hunter